Search results
Results from the WOW.Com Content Network
Evidence-based medicine may reduce adverse events, especially those involving incorrect diagnosis, outdated or risky tests or procedures, or medication overuse. Clinical guidelines provide a common framework for improving communication among clinicians, patients and non-medical purchasers of health care.
The Safer Patients Initiative, [43] one of the Foundation's quality and performance improvement programs, targets reducing medication-related adverse events and errors, reducing infections associated with intensive care units or surgery and improving organizational culture, leadership and expertise in measuring improvement. The goal of the ...
1. **Improved Clinical Decision Making**: CDSS provides evidence-based recommendations, reducing errors and variability in clinical practice. 2. **Enhanced Patient Safety**: Alerts for drug interactions, allergies, and potential adverse events help prevent medical errors and improve patient outcomes. 3.
The Institute for Safe Medication Practices (ISMP) is an American 501(c)(3) organization focusing on the prevention of medication errors and promoting safe medication practices. [1] It is affiliated with ECRI .
Evidence-based medicine (EBM) is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients. ...[It] means integrating individual clinical expertise with the best available external clinical evidence from systematic research."
Variations in healthcare provider training & experience [45] [52] and failure to acknowledge the prevalence and seriousness of medical errors also increase the risk. [53] [54] The so-called July effect occurs when new residents arrive at teaching hospitals, causing an increase in medication errors according to a study of data from 1979 to 2006.
Despite ample evidence of the potential to reduce medication errors, competing systems of barcoding and electronic prescribing have slowed adoption of this technology by doctors and hospitals in the United States, due to concern with interoperability and compliance with future national standards. [27]
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand-name or generic drugs. [1] The REMS program was formalized in 2007.